Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Malignant Neoplasm of Breast
Interventions: DRUG: Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
Sponsor: AryoGen Pharmed Co.